RT Journal Article
SR Electronic
T1 Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.03.21264320
DO 10.1101/2021.10.03.21264320
A1 Brumme, Zabrina L.
A1 Mwimanzi, Francis
A1 Lapointe, Hope R.
A1 Cheung, Peter
A1 Sang, Yurou
A1 Duncan, Maggie C.
A1 Yaseen, Fatima
A1 Agafitei, Olga
A1 Ennis, Siobhan
A1 Ng, Kurtis
A1 Basra, Simran
A1 Lim, Li Yi
A1 Kalikawe, Rebecca
A1 Speckmaier, Sarah
A1 Moran-Garcia, Nadia
A1 Young, Landon
A1 Ali, Hesham
A1 Ganase, Bruce
A1 Umviligihozo, Gisele
A1 Omondi, F. Harrison
A1 Atkinson, Kieran
A1 Sudderuddin, Hanwei
A1 Toy, Junine
A1 Sereda, Paul
A1 Burns, Laura
A1 Costiniuk, Cecilia T.
A1 Cooper, Curtis
A1 Anis, Aslam H.
A1 Leung, Victor
A1 Holmes, Daniel
A1 DeMarco, Mari L.
A1 Simons, Janet
A1 Hedgcock, Malcolm
A1 Romney, Marc G.
A1 Barrios, Rolando
A1 Guillemi, Silvia
A1 Brumme, Chanson J.
A1 Pantophlet, Ralph
A1 Montaner, Julio S.G.
A1 Niikura, Masahiro
A1 Harris, Marianne
A1 Hull, Mark
A1 Brockman, Mark A.
YR 2021
UL http://medrxiv.org/content/early/2021/10/15/2021.10.03.21264320.abstract
AB Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain incompletely understood. We measured circulating antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, ACE2 displacement and live viral neutralization activities one month following the first and second COVID-19 vaccine doses in 100 adult PLWH and 152 controls. All PLWH were receiving suppressive antiretroviral therapy, with median CD4+ T-cell counts of 710 (IQR 525-935) cells/mm3. Nadir CD4+ T-cell counts ranged as low as <10 (median 280; IQR 120-490) cells/mm3. After adjustment for sociodemographic, health and vaccine-related variables, HIV infection was significantly associated with 0.2 log10 lower anti-RBD antibody concentrations (p=0.03) and ∼11% lower ACE2 displacement activity (p=0.02), but not lower viral neutralization (p=0.1) after one vaccine dose. Following two doses however, HIV was no longer significantly associated with the magnitude of any response measured. Rather, older age, a higher burden of chronic health conditions, and having received two ChAdOx1 doses (versus a heterologous or dual mRNA vaccine regimen) were independently associated with lower responses. After two vaccine doses, no significant correlation was observed between the most recent or nadir CD4+ T-cell counts and vaccine responses in PLWH. These results suggest that PLWH with well-controlled viral loads on antiretroviral therapy and CD4+ T-cell counts in a healthy range will generally not require a third COVID-19 vaccine dose as part of their initial immunization series, though other factors such as older age, co-morbidities, vaccine regimen type, and durability of vaccine responses will influence when this group may benefit from additional doses. Further studies of PLWH who are not receiving antiretroviral treatment and/or who have low CD4+ T-cell counts are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from Genome BC, the Michael Smith Foundation for Health Research, and the BCCDC Foundation for Public Health through a rapid SARS-CoV-2 vaccine research initiative in BC award (VAC-009 to ZLB, MAB). It was also supported by the Public Health Agency of Canada (PHAC) through two COVID-19 Immunology Task Force (CITF) COVID-19 Awards (to ZLB, MGR, MAB and to CTC, CC, AHA), the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (to CJB, MAB, MN, MLD, RP, ZLB), a British Columbia Ministry of Health Providence Health Care Research Institute COVID-19 Research Priorities Grant (to CJB), the CIHR Canadian HIV Trials Network (CTN) (to AHA) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for Health Research. LYL was supported by an SFU Undergraduate Research Award. GU and FHO are supported by Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # DEL 15 006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. HS is supported by a CGS-M award from the Canadian Institutes of Health Research (CIHR). The views expressed in this publication are those of the authors and not necessarily those of PHAC, CITF, AAS, NEPAD Agency, Wellcome Trust, the Canadian or UK governments or other funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards. All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to the corresponding author. As per funder requirements, all data will also be deposited into a national database at the conclusion of the study.